Sangamo BioSciences Reports Third Quarter 2008 Financi...(t encodes a ZFP transcription fact...)

transcription factor (ZFP TF(TM)), designed to upregulate the vascular

endothelial growth factor-A (VEGF-A) gene.

* Official launch of Sigma-Aldrich CompoZr(TM) platform of zinc finger

nuclease (ZFN) reagents for gene-editing. In September, Sangamo's

partner, Sigma-Aldrich Corporation (Nasdaq: SIAL), the exclusive

distributor of ZFP products for research applications, launched sales

of CompoZr ZFN reagents. The CompoZr ZFN platform of reagents is

expected to provide researchers with the ability to target and

precisely manipulate the genome of living cells, resulting in cell

lines or whole organisms with defined gene deletions, insertions, or

corrections. Initially offered as a customized service for developing

ZFNs for specific gene targets, the CompoZr ZFN platform will

eventually include ZFN-based kits for targeted transgene insertion and

a catalog of off-the-shelf reagents for commonly studied gene targets,

gene families, and pathways. For more information on Sigma-Aldrich's

CompoZr zinc finger nuclease technology platform, visit

http://www.compozrzfn.com or contact a sales representative at

zfn@sial.com .

Conference Call

Sangamo will host a conference call today, October 29, 2008 at 5:00 p.m. ET, which will be open to the public. The call will also be webcast live and can be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under "Events and Presentations" http://inve
'/>"/>